Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups

Marlise R. Luskin, Ju Whei Lee, Hugo F. Fernandez, Omar Abdel-Wahab, John M. Bennett, Rhett P. Ketterling, Hillard M. Lazarus, Ross L. Levine, Mark R. Litzow, Elisabeth M. Paietta, Jay P. Patel, Janis Racevskis, Jacob M. Rowe, Martin S. Tallman, Zhuoxin Sun, Selina M. Luger

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

The initial report of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group trial E1900 (#NCT00049517) showed that induction therapy with high-dose (HD) daunorubicin (90 mg/m2) improved overall survival in adults 2), HD daunorubicin is associated with a hazard ratio (HR) for death of 0.74 (P 5 .001). Younger patients (

Original languageEnglish (US)
Pages (from-to)1551-1558
Number of pages8
JournalBlood
Volume127
Issue number12
DOIs
StatePublished - Mar 24 2016

Fingerprint

Daunorubicin
Cytogenetics
Radiology
Oncology
Hazards
Imaging techniques
Survival
Research
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Luskin, M. R., Lee, J. W., Fernandez, H. F., Abdel-Wahab, O., Bennett, J. M., Ketterling, R. P., ... Luger, S. M. (2016). Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. Blood, 127(12), 1551-1558. https://doi.org/10.1182/blood-2015-07-657403

Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. / Luskin, Marlise R.; Lee, Ju Whei; Fernandez, Hugo F.; Abdel-Wahab, Omar; Bennett, John M.; Ketterling, Rhett P.; Lazarus, Hillard M.; Levine, Ross L.; Litzow, Mark R.; Paietta, Elisabeth M.; Patel, Jay P.; Racevskis, Janis; Rowe, Jacob M.; Tallman, Martin S.; Sun, Zhuoxin; Luger, Selina M.

In: Blood, Vol. 127, No. 12, 24.03.2016, p. 1551-1558.

Research output: Contribution to journalArticle

Luskin, MR, Lee, JW, Fernandez, HF, Abdel-Wahab, O, Bennett, JM, Ketterling, RP, Lazarus, HM, Levine, RL, Litzow, MR, Paietta, EM, Patel, JP, Racevskis, J, Rowe, JM, Tallman, MS, Sun, Z & Luger, SM 2016, 'Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups', Blood, vol. 127, no. 12, pp. 1551-1558. https://doi.org/10.1182/blood-2015-07-657403
Luskin MR, Lee JW, Fernandez HF, Abdel-Wahab O, Bennett JM, Ketterling RP et al. Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. Blood. 2016 Mar 24;127(12):1551-1558. https://doi.org/10.1182/blood-2015-07-657403
Luskin, Marlise R. ; Lee, Ju Whei ; Fernandez, Hugo F. ; Abdel-Wahab, Omar ; Bennett, John M. ; Ketterling, Rhett P. ; Lazarus, Hillard M. ; Levine, Ross L. ; Litzow, Mark R. ; Paietta, Elisabeth M. ; Patel, Jay P. ; Racevskis, Janis ; Rowe, Jacob M. ; Tallman, Martin S. ; Sun, Zhuoxin ; Luger, Selina M. / Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. In: Blood. 2016 ; Vol. 127, No. 12. pp. 1551-1558.
@article{6d77590798d942a08b60b9341a1a9d6c,
title = "Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups",
abstract = "The initial report of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group trial E1900 (#NCT00049517) showed that induction therapy with high-dose (HD) daunorubicin (90 mg/m2) improved overall survival in adults 2), HD daunorubicin is associated with a hazard ratio (HR) for death of 0.74 (P 5 .001). Younger patients (",
author = "Luskin, {Marlise R.} and Lee, {Ju Whei} and Fernandez, {Hugo F.} and Omar Abdel-Wahab and Bennett, {John M.} and Ketterling, {Rhett P.} and Lazarus, {Hillard M.} and Levine, {Ross L.} and Litzow, {Mark R.} and Paietta, {Elisabeth M.} and Patel, {Jay P.} and Janis Racevskis and Rowe, {Jacob M.} and Tallman, {Martin S.} and Zhuoxin Sun and Luger, {Selina M.}",
year = "2016",
month = "3",
day = "24",
doi = "10.1182/blood-2015-07-657403",
language = "English (US)",
volume = "127",
pages = "1551--1558",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "12",

}

TY - JOUR

T1 - Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups

AU - Luskin, Marlise R.

AU - Lee, Ju Whei

AU - Fernandez, Hugo F.

AU - Abdel-Wahab, Omar

AU - Bennett, John M.

AU - Ketterling, Rhett P.

AU - Lazarus, Hillard M.

AU - Levine, Ross L.

AU - Litzow, Mark R.

AU - Paietta, Elisabeth M.

AU - Patel, Jay P.

AU - Racevskis, Janis

AU - Rowe, Jacob M.

AU - Tallman, Martin S.

AU - Sun, Zhuoxin

AU - Luger, Selina M.

PY - 2016/3/24

Y1 - 2016/3/24

N2 - The initial report of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group trial E1900 (#NCT00049517) showed that induction therapy with high-dose (HD) daunorubicin (90 mg/m2) improved overall survival in adults 2), HD daunorubicin is associated with a hazard ratio (HR) for death of 0.74 (P 5 .001). Younger patients (

AB - The initial report of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group trial E1900 (#NCT00049517) showed that induction therapy with high-dose (HD) daunorubicin (90 mg/m2) improved overall survival in adults 2), HD daunorubicin is associated with a hazard ratio (HR) for death of 0.74 (P 5 .001). Younger patients (

UR - http://www.scopus.com/inward/record.url?scp=84962304176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962304176&partnerID=8YFLogxK

U2 - 10.1182/blood-2015-07-657403

DO - 10.1182/blood-2015-07-657403

M3 - Article

VL - 127

SP - 1551

EP - 1558

JO - Blood

JF - Blood

SN - 0006-4971

IS - 12

ER -